8-K - VNRX - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

**** Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 16, 2024

VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware	001-36833	91-1949078
---	---	---
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
1489 West Warm Springs Road, Suite 110<br><br>Henderson, Nevada	89014
---	---
(Address of Principal Executive Offices)	(Zip Code)

+1 (646) 650-1351

(Registrant’s telephone number, including area code )

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share	VNRX	NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

VOLITIONRX LIMITED

Form 8-K

Current Report

Item 7.01. Regulation FD Disclosure.

From September 16, 2024, VolitionRx Limited (the “Company”) is making available to third parties, including through its licensing adviser, PharmaVentures Limited, a document providing a brief introduction to certain components of the Company’s oncology portfolio available to out license. A copy of the document is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.

The information contained in, or incorporated into, this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit<br><br>Number	**<br><br>Description**
99.1	Brief Overview of Certain Oncology Assets, issued September 16, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VOLITIONRX LIMITED
Date: September 16, 2024	By:	/s/ Cameron Reynolds
		Cameron Reynolds
		Chief Executive Officer & President
3
---

EXHIBIT INDEX

Exhibit<br><br>Number	**<br><br>Description**
99.1	Brief Overview of Certain Oncology Assets, issued September 16, 2024.
4
---

vnrx_ex991.htm EXHIBIT 99.1

2